The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters

Combinations of direct-acting antivirals are needed to minimize drug resistance mutations and stably suppress replication of RNA viruses. Currently, there are limited therapeutic options against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and testing of a number of drug regimen...

Descripción completa

Detalles Bibliográficos
Autores principales: Shytaj, Iart Luca, Fares, Mohamed, Gallucci, Lara, Lucic, Bojana, Tolba, Mahmoud M., Zimmermann, Liv, Adler, Julia M., Xing, Na, Bushe, Judith, Gruber, Achim D., Ambiel, Ina, Taha Ayoub, Ahmed, Cortese, Mirko, Neufeldt, Christopher J., Stolp, Bettina, Sobhy, Mohamed Hossam, Fathy, Moustafa, Zhao, Min, Laketa, Vibor, Diaz, Ricardo Sobhie, Sutton, Richard E., Chlanda, Petr, Boulant, Steeve, Bartenschlager, Ralf, Stanifer, Megan L., Fackler, Oliver T., Trimpert, Jakob, Savarino, Andrea, Lusic, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941859/
https://www.ncbi.nlm.nih.gov/pubmed/35229634
http://dx.doi.org/10.1128/mbio.03705-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941859/
https://www.ncbi.nlm.nih.gov/pubmed/35229634
http://dx.doi.org/10.1128/mbio.03705-21

Ejemplares similares